We thank Hammond et al. for having provided technical arguments explaining why they consider the finding of mutant JAK2 copies in normal granulocytes as polymerase chain reaction (PCR) artefacts. 1 According to the technical details given, we can understand why the discrimination between the wild-type and mutant JAK2 allele is not absolute as it is only based on the specificity of the 3 0 -end base of a primer. Our methodology is clearly different. 2 Furthermore, the positive results that we obtained were highly reproducible: in patients who showed to be initially positive, the mutation was recurrently found in repeated PCR performed on both genomic DNA and cDNA preparations. Moreover, some of the positive PCR results were confirmed by sequencing. Therefore, we have good reasons to consider that the JAK2V617F mutation found in some of our normal patients is not a PCR artefact.
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide Leukemia (2007 Leukemia ( ) 21, 818-820. doi:10.1038 published online 15 February 2007 We read with interest the International Uniform Response Criteria for multiple myeloma (MM) by Durie et al., 1 and congratulate the authors on this important step toward a more standardized approach to assessing response in MM. We believe that such an approach will help gauge the relative value of the newer biological therapies for MM. Indeed, response rates are often the first demonstration of clinical activity of new anticancer therapies, which are then further assessed by progression and survival outcomes. Although the concept of unifying response criteria appears intuitive, we were unable to find any literature that actually compares response rates using different criteria in the same cohorts of patients. In this report, we explore and illustrate the impact and influence of methods of response assessment using published studies of thalidomide and bortezomib for the treatment of MM. These data emphasize the need to introduce the standardized criteria proposed by Durie et al. as soon as possible.
As discussed by Durie et al., there are three primary sets of criteria that are used for determining response in MM (Table 1) : (1) M-protein reduction alone, based on criteria developed by the Chronic Leukemia and Myeloma Task Force of the National Cancer Institute; 2 of note, although these guidelines did not define the degree of response in terms of complete response (CR) or partial response (PR), the extent of M-protein reduction has since been incorporated into clinical trial designs to develop protocol-specific definitions of CR, PR and minimal response (MR). (2) Southwest Oncology Group (SWOG) criteria, tion criteria, which are more rigorous and stringent than the aforementioned criteria sets. Using the Bladé criteria, complete responders must have 100% reduction in both serum and urine M-protein and all responses must be maintained for X6 weeks. The M-protein reduction alone criteria comprise the same number of response categories as the Bladé criteria (i.e., CR, PR and MR), but do not require the same number of diagnostic indicators (i.e., plasmacytoma level, percentage of plasma cells in the bone marrow and extent of bone disease) or a minimum response duration.
We examined nine studies of single-agent thalidomide in relapsed or refractory MM, which were recently included in a pooled analysis 5 ( Table 2 ). The median number of prior therapies, when reported, ranged from 2 to 4. The studies typically used a starting thalidomide dose of 100-200 mg/day, which was escalated to a maximum of 400-800 mg/day. These studies were also similar in that most defined response based on M-protein reduction alone criteria, with the exception of two studies by Neben et al. and Huang et al. , which used the Bladé criteria (Table 2) . Those using M-protein alone criteria were not always consistent, however, in their definitions of response categories and the source of M-protein measurement (serum vs urine), and the method of detecting serum M-protein (electrophoresis or immunofixation) was not always clarified.
The pooled CR and PR rates were 1.6 and 26.0%, respectively, yielding an overall response rate of 28% in patients with relapsed or refractory MM. 5 In seven of the nine trials, the overall response rate (CR þ PR) ranged from 20 to 30%, whereas the CR rate ranged from 0 to 2% (Table 2 ). Higher overall response rates were reported by respectively ), yet it is important to note that these studies used the M-protein alone criteria to evaluate response. In contrast, the studies conducted by Neben et al. and Huang et al. were the only two that used the more rigorous Bladé criteria. The overall response rate reported by Neben et al. was 20.5%, including one (1.2%) CR, and Huang et al. reported a 20.0% overall response rate with no patients achieving CR. These results provide a useful demonstration of the important impact that response rate criteria have on the value of the response rate achieved.
In the phase II SUMMIT trial of bortezomib for relapsed or refractory MM, 6 responses were assessed according to the Bladé criteria. The population was very heavily pretreated with a median of six prior therapies (range, 2-15). Of 193 evaluable patients, seven patients (3.6%) achieved a CR with an additional A designation of PD only requires that at least one of the criteria within this category be met.
c Stable bone disease was defined as no increase in size or number of lytic bone lesions.
Letters to the Editor 12 patients (6.2%) achieving a near-CR (satisfying all CR criteria with the exception that M-protein was detectable by immunofixation, although undetectable by electrophoresis). The overall response rate (CR þ PR) was 27% according to the Bladé criteria, rising to 37% when measured according to the M-protein alone criteria -the difference between these two response rates illustrates how large an impact that response criteria can have on reported response rates. Moreover, stricter criteria for assessing response may be better at predicting outcome.
According to a landmark analysis, the subset of patients achieving a CR or PR after two bortezomib cycles had significantly longer survival relative to all other patients (P ¼ 0.007). On the basis of an extended follow-up report, 7 median overall survival was 17.0 months for all patients in the SUMMIT trial and had not yet been reached for responding patients after a 23-month follow-up. In the subsequent phase III APEX trial, 8 involving 669 patients who had received a median of two prior therapies, patients were randomized to receive either bortezomib or high-dose dexamethasone. Originally published overall response rates (CR þ PR), using the Bladé criteria, were 38% for bortezomib versus 18% with dexamethasone (Po0.001); 8 an updated analysis that included 22 months of follow-up demonstrated a higher overall response rate of 43% for bortezomib (34% PR þ 9% CR) (Richardson P et al. Blood 2005; 106: 715a-716a . abstract 2547 and poster presentation). When evaluated according to M-protein reduction alone criteria, the overall response rate further improved to 56%, including a 19% CR rate.
Another important aspect of the Durie et al. publication is the definitions of disease progression and relapse. We would have liked to explore how response assessment translates into differences in time to progression (TTP), but such analyses would be difficult to interpret given that the definition of progression would inherently vary according to the response criteria used. For example, TTP after a Bladé-defined CR would be defined differently than TTP by the SWOG criteria. Moreover, we would also recommend that consideration be made to introduce standard monitoring criteria, such as the frequency of disease assessment, to standardize further the measurement of progression outcomes.
In conclusion, we believe that until the new criteria proposed by Durie et al. become routine in all MM clinical trials, it is important that clinicians pay careful consideration to the criteria used to measure response when they are making comparisons of data across MM clinical trials. 
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